Novartis said that a Phase 3 trial of its new drug for acromegaly, pasireotide, is superior to the current standard of care for the disease. The current standard of care, Sandostatin (octreotide), is an older Novartis medicine. ---Subscribe to MedNous to access this article--- Research & University News Company News